PROTON-TECHNOLOGIES
4.4.2022 12:09:07 CEST | Business Wire | Press release
The Kopahawakenum (Cree for “Kicking up the dust”) 15-Megawatt Flare Gas to Power Facility announced by SaskPower, Flying Dust First Nation, and Genalta Power, online 2023, plans to purchase Flare Gas from Proton Canada’s nearby asset, according to a letter of intent recently signed between the CEO of Genalta, Paul Miller, and the CEO of Proton, Grant Strem.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220404005320/en/
To ensure sufficient supply for the Kopahawakenum Facility, plus Proton’s own 4.2 MW Power Purchase Agreement and other off-takers, the plan is to install a Cryogenic Air Separation unit (ASU), for injecting pure oxygen and third-party CO2 into Proton’s underground oil deposit to increase hydrogen-productive reactions.
Cold gases from the ASU can separate produced gases by freezing or liquifying these at various cold temperatures at the surface using passive heat exchange. Unwanted components like CO2 are planned to go back into the ground, where reactions can cause them to solidify into forms like carbonate rock. Proton has been demonstrating their patented method for accelerating carbonate creation within pores in the earth, by injecting steam boiler blow-down (reactive waste stream fluid) into their CO2-rich subsurface environment.
Proton’s PPA has final approval and plans and designs for construction are underway. Genalta’s Kopahawakenum PPA is conditionally approved under Saskatchewan’s Oil and Gas Processing Investment Incentive (OGPII), and the Saskatchewan Petroleum Innovation Incentive (SPII), which provide royalty credits at a rate of 15% and 25% of expenses respectively, after the private investments are made.
Grant Strem said, “I want to thank Genalta, the government of Saskatchewan, the First Nations Power Authority, and the Flying Dust First Nation for boldly and creatively enabling improvements over our current energy systems. There will be economic and ecological benefits from this first project, and we believe also from hundreds or even thousands of larger similar projects around the world in the long course of time, thanks to the efforts and investments of those involved in this global first. Proton is very pleased to have Genalta as our creative, positive customer. This flex-fuel offtake deal helps justify and enable a “small enough to be fast” commercial demonstration of core elements of Proton’s method to produce low cost hydrogen while sequestering carbon inside the earth as rock. Many oil assets late in their productive life cycle can be repurposed to make clean energy, leveraging the infrastructure and investments of the past. We plan to expand as fast as we can afford to.”
Paul Miller said, “Kopahawakenum is a cornerstone project that will help the energy industry in Saskatchewan to meet the goals announced by the federal government to reduce GHG emissions 30% in the industry by 2030. Additionally it will be including First Nations in energy stewardship in the province in a meaningful way, creating long term jobs and a replicable approach to utilizing Flare and Vent Gas for power generation. Proton’s fuel supply is critical for the Kopahawakenum project. We thank Proton for their collaboration and support; their visionary project is a game changer in the energy industry with tremendous potential to provide large quantities of emissions free fuel at an economical price to the global market. We are proud to be working with them to further reduce emissions in Saskatchewan and hope to utilize their clean Hydrogen in the future as we continue to expand our clean power base in the province.”
For more information please contact info@proton.energy or investorrelations@proton.energy .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220404005320/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
